The Schall Law Firm Announces An Inquiry Into Allegations Against Zoetis Inc. (NYSE:ZTS) And Encourages Investors Who Have Incurred Losses To Reach Out
LOS ANGELES, CA / ACCESSWIRE / June 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Declares An Investigation Into Claims Against Zoetis Inc. (NYSE:ZTS) And Urges Investors Who Have Suffered Losses To Make Contact
LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Announces A Probe Into Allegations Against Zoetis Inc. (NYSE:ZTS) And Encourages Investors With Losses To Reach Out
LOS ANGELES, CA / ACCESSWIRE / June 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Declares an Examination into Accusations Against Zoetis Inc. and Urges Investors with Losses to Communicate
LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ZTS INVESTIGATION PROGRESS ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
IMPORTANT INVESTIGATION UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zoetis Inc. - ZTS
NEW YORK, NY / ACCESSWIRE / June 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE:ZTS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
IMPORTANT INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
IMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Zoetis: Why The Focus On Companion Animal Segment Will Pay Off
Zoetis stock has underperformed the market since my previous article, but long-term investors should double down today due to the strengthening companion animal business. The companion animal segment is growing rapidly, driven by factors such as the humanization of pets and increasing awareness of pet healthcare. Zoetis is well-positioned to benefit from the growth of the companion animal market, particularly in Latin America.
Zoetis Inc. (NYSE:ZTS) Shares Purchased by Meridian Wealth Management LLC
Meridian Wealth Management LLC grew its position in Zoetis Inc. (NYSE:ZTS – Free Report) by 18.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,541 shares of the company’s stock after buying an additional 239 shares during the quarter. Meridian Wealth Management LLC’s holdings in Zoetis were worth $304,000 at the end of the most recent quarter. Other institutional investors and hedge funds have also made changes to their positions in the company. Vaughan Nelson Investment Management L.P. acquired a new position in shares of Zoetis in the third quarter valued at approximately $176,219,000. Alphinity Investment Management Pty Ltd increased its stake in shares of Zoetis by 214.7% during the 4th quarter. Alphinity Investment Management Pty Ltd now owns 824,148 shares of the company’s stock valued at $162,662,000 after acquiring an additional 562,259 shares during the last quarter. International Assets Investment Management LLC boosted its position in shares of Zoetis by 27,671.0% in the fourth quarter. International Assets Investment Management LLC now owns 479,328 shares of the company’s stock worth $94,605,000 after acquiring an additional 477,602 shares during the last quarter. Envestnet Asset Management Inc. raised its stake in Zoetis by 34.8% during the third quarter. Envestnet Asset Management Inc. now owns 1,562,044 shares of the company’s stock worth $271,764,000 after purchasing an additional 403,164 shares during the period. Finally, Natixis Advisors L.P. boosted its holdings in shares of Zoetis by 53.9% in the 3rd quarter. Natixis Advisors L.P. now owns 941,219 shares of the company’s stock valued at $163,753,000 after purchasing an additional 329,543 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors. Zoetis Trading Up 0.2 % Shares of ZTS stock opened at $174.06 on Monday. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The firm has a market capitalization of $79.42 billion, a PE ratio of 33.54, a price-to-earnings-growth ratio of 2.70 and a beta of 0.86. The stock has a fifty day moving average of $164.65 and a two-hundred day moving average of $179.52. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. Zoetis (NYSE:ZTS – Get Free Report) last announced its earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The firm had revenue of $2.19 billion during the quarter, compared to analyst estimates of $2.14 billion. During the same quarter in the prior year, the firm posted $1.31 EPS. Zoetis’s revenue was up 9.5% compared to the same quarter last year. As a group, research analysts expect that Zoetis Inc. will post 5.77 EPS for the current year. Insider Buying and Selling In other news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $173.33, for a total transaction of $159,983.59. Following the sale, the executive vice president now owns 15,723 shares in the company, valued at $2,725,267.59. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by company insiders. Wall Street Analysts Forecast Growth A number of equities research analysts have issued reports on the company. Piper Sandler reissued an “overweight” rating and set a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. HSBC reduced their price objective on Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Stifel Nicolaus reduced their target price on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, April 30th. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Finally, The Goldman Sachs Group lowered their price objective on Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research note on Monday, May 6th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $211.75. Read Our Latest Stock Analysis on Zoetis About Zoetis (Free Report) Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
